Core Insights - The company, Hongbo Pharmaceutical, has announced that its DiOrion platform has provided technical support for a total of 95 new drug projects as of August 2025 [1] - Out of these projects, 7 have entered the clinical trial phase, indicating progress in drug development [1] - The platform has served a total of 45 clients across multiple therapeutic areas, showcasing its broad applicability in the pharmaceutical industry [1] Platform Development - The DiOrion platform is a self-developed enabling platform for drug research and development, which has completed local deployment and is continuously iterating and upgrading [1] - It has integrated 9 core modules that cover the entire process of early-stage new drug development [1]
泓博医药：截至2025年8月公司DiOrion平台已累计为95个新药项目提供技术支持